产品说明书
Orbifloxacin
 |
同义名 : | CP-104354;CP 104,354;Orbax |
| CAS号 : | 113617-63-3 | |
| 货号 : | A1453840 | |
| 分子式 : | C19H20F3N3O3 | |
| 纯度 : | 99% | |
| 分子量 : | 395.376 | |
| MDL号 : | MFCD00864858 | |
| 存储条件： |
粉末 Inert atmosphere,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 5 mg/mL(12.65 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Orbifloxacin is a fluoroquinolone drug used widely in companion animal medicine. At twice the MIC, the PAEs (post-antibiotic effects) of orbifloxacin ranged from -0.28-0.93 h (mean, 0.29 h) for E. coli and -0.18-1.18 h (mean, 0.37 h) for P. aeruginosa[2]. Orbifloxacin could have success against susceptible mastitis pathogens in goats[3]. Oral ORB (Orbifloxacin, 2.5 mg/kg and 5 mg/kg) may alter the total counts and composition of fecal coliform, but is unlikely to yield highly fluoroquinolone-resistant mutants of E. coli and C. freundii in cats, possibly because of the high drug concentration in feces[4]. In addition, orbifloxacin was an effective, safe, and convenient antibiotic for the treatment of superficial and deep staphylococcal pyoderma in dogs[5]. Orbifloxacin and the peptide AK15 possess significant bactericidal activity against Mycobacterium tuberculosis (Mtb) in vitro. Orbifloxacin also showed an effective ability on the clearance of intracellular Mtb and protect mice from a strong inflammatory response but not AK15[6]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.53mL 0.51mL 0.25mL |
12.65mL 2.53mL 1.26mL |
25.29mL 5.06mL 2.53mL |
| 参考文献 |
|---|